RABEPRAZOLE SODIUM

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H20N3O3S.Na
Molecular Weight	381.424
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].COCCCOC1=CC=NC(C[S+]([O-])C2=NC3=C([N-]2)C=CC=C3)=C1C

InChI

InChIKey=KRCQSTCYZUOBHN-UHFFFAOYSA-N

InChI=1S/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1

HIDE SMILES / InChI

Molecular Formula	C18H21N3O3S
Molecular Weight	359.443
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10551440
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20973lbl.pdf

Rabeprazole sodium was discovered by Eisai Co., Ltd. Janssen Pharmaceutica N.V. and Eisai Co., Ltd. have a strategic alliance in which Eisai and Janssen-Cilag co-promote the drug in Germany and the U.K. In the US rabeprazole sodium is co-promoted under the brand name AcipHex by Eisai Inc. and Janssen Pharmaceutica Inc. Pariet is available through Janssen-Cilag in most other countries excluding Japan and some Asian countries. Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. Rabeprazole is a prodrug and is converted to the active sulphenamide form in the acid environment of the parietal cells. Rabeprazole is used to heal and maintain the healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD), for healing Duodenal Ulcers, and for treatment of pathological hypersecretory conditions such as Zollinger-Ellison Syndrome. Rabeprazole suppresses gastric acid secretion by inhibiting the gastric H+, K+ATPase at the secretory surface of the gastric parietal cell and does not exhibit anticholinergic or histamine H2-receptor antagonist properties. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor which blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfonamide.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Potassium-transporting ATPase 31 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23350044	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Erosive or ulcerative gastroesophageal reflux disease 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20973lbl.pdf	Primary	Approved 8429	ACIPHEX Approved Use ACIPHEX is a proton-pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( ) 1.1 Maintenance of Healing of Erosive or Ulcerative GERD ( ) 1.2 Treatment of Symptomatic GERD ( ) 1.3 Healing of Duodenal Ulcers ( ) 1.4 Eradication to Reduce the Risk of Duodenal Ulcer Recurrence ( ) Helicobacter pylori 1.5 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ( ) 1.6 In adolescent patients 12 years of age and older for: Short-term treatment of Symptomatic GERD ( ) 1.7 In pediatric patients 1 to 11 years of age for: Treatment of GERD ( ) 1.8 1.1 Healing of Erosive or Ulcerative GERD in Adults ACIPHEX is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered. 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults ACIPHEX is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. 1.3 Treatment of Symptomatic GERD in Adults ACIPHEX is indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults 1.4 Healing of Duodenal Ulcers in Adults ACIPHEX is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. 1.5 Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Helicobacter pylori ACIPHEX in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate . Eradication of has been shown to reduce the risk of duodenal ulcer recurrence [ and Launch Date 1999
Duodenal ulcer 42 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20973lbl.pdf	Primary	Approved 8429	ACIPHEX Approved Use ACIPHEX is a proton-pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( ) 1.1 Maintenance of Healing of Erosive or Ulcerative GERD ( ) 1.2 Treatment of Symptomatic GERD ( ) 1.3 Healing of Duodenal Ulcers ( ) 1.4 Eradication to Reduce the Risk of Duodenal Ulcer Recurrence ( ) Helicobacter pylori 1.5 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ( ) 1.6 In adolescent patients 12 years of age and older for: Short-term treatment of Symptomatic GERD ( ) 1.7 In pediatric patients 1 to 11 years of age for: Treatment of GERD ( ) 1.8 1.1 Healing of Erosive or Ulcerative GERD in Adults ACIPHEX is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered. 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults ACIPHEX is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. 1.3 Treatment of Symptomatic GERD in Adults ACIPHEX is indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults 1.4 Healing of Duodenal Ulcers in Adults ACIPHEX is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. 1.5 Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Helicobacter pylori ACIPHEX in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate . Eradication of has been shown to reduce the risk of duodenal ulcer recurrence [ and Launch Date 1999
Zollinger-Ellison syndrome 17 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20973lbl.pdf	Primary	Approved 8429	ACIPHEX Approved Use ACIPHEX is a proton-pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( ) 1.1 Maintenance of Healing of Erosive or Ulcerative GERD ( ) 1.2 Treatment of Symptomatic GERD ( ) 1.3 Healing of Duodenal Ulcers ( ) 1.4 Eradication to Reduce the Risk of Duodenal Ulcer Recurrence ( ) Helicobacter pylori 1.5 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ( ) 1.6 In adolescent patients 12 years of age and older for: Short-term treatment of Symptomatic GERD ( ) 1.7 In pediatric patients 1 to 11 years of age for: Treatment of GERD ( ) 1.8 1.1 Healing of Erosive or Ulcerative GERD in Adults ACIPHEX is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered. 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults ACIPHEX is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. 1.3 Treatment of Symptomatic GERD in Adults ACIPHEX is indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults 1.4 Healing of Duodenal Ulcers in Adults ACIPHEX is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. 1.5 Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Helicobacter pylori ACIPHEX in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate . Eradication of has been shown to reduce the risk of duodenal ulcer recurrence [ and Launch Date 1999

C_max

Value	Dose	Analyte	Population
1.54 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30321480	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	RABEPRAZOLE blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.406 μg/mL REVIEW https://www.ncbi.nlm.nih.gov/pubmed/28294690	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	RABEPRAZOLE unknown	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
2.5 μg/mL REVIEW https://www.ncbi.nlm.nih.gov/pubmed/28294690	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	RABEPRAZOLE unknown	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
2.15 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30321480	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	RABEPRAZOLE blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.809 μg × h/mL REVIEW https://www.ncbi.nlm.nih.gov/pubmed/28294690	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	RABEPRAZOLE unknown	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
5.212 μg × h/mL REVIEW https://www.ncbi.nlm.nih.gov/pubmed/28294690	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	RABEPRAZOLE unknown	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
3.46 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30321480	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	RABEPRAZOLE blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.02 h REVIEW https://www.ncbi.nlm.nih.gov/pubmed/28294690	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	RABEPRAZOLE unknown	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1.21 h REVIEW https://www.ncbi.nlm.nih.gov/pubmed/28294690	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	RABEPRAZOLE unknown	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
40 mg single, oral Recommended Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9701531 Page: p.670	healthy, 22.5 ± 3.9 n = 8 Health Status: healthy Age Group: 22.5 ± 3.9 Sex: M Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/9701531 Page: p.670	Sources: https://pubmed.ncbi.nlm.nih.gov/9701531 Page: p.670
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9354209 Page: p.978	unhealthy, 41 n = 20 Health Status: unhealthy Condition: Gastroesophageal reflux disease Age Group: 41 Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/9354209 Page: p.978	Sources: https://pubmed.ncbi.nlm.nih.gov/9354209 Page: p.978
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12094846 Page: p.1337	unhealthy, 45.5 n = 68 Health Status: unhealthy Condition: Gastroesophageal reflux disease Age Group: 45.5 Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/12094846 Page: p.1337	Sources: https://pubmed.ncbi.nlm.nih.gov/12094846 Page: p.1337

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8768	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8768
ChemicalBook	CB3680731	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3680731
MolPort	MolPort-005-935-061	https://www.molport.com/shop/molecule-link/MolPort-005-935-061
eMolecules	601413	https://www.emolecules.com/cgi-bin/more?vid=601413

PubMed

Title	Date	PubMed
[Pariet in eradication therapy plans].	2002	12353394
[Seven-day antihelicobacter therapy of duodenal ulcer associated with Helicobacter pylori and prospects for treating patients].	2002	12353382
[Effectiveness of pariet (rabeprazole) in the treatment of gastroesophageal reflux disease (at the reflux-esophagitis stage)].	2002	12271586
Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.	2002	12240793
[Regeneration of the esophagus epitheliocytes. Evaluation of pariet efficacy in the treatment of patients with reflux esophagitis].	2002	12046386
[Inhibitors of proton pump in the treatment of non-ulcer functional dyspepsia of the reflux-like type].	2002	12046384
Rabeprazole: quest for the best PPI.	2002	11931540
The effects of rabeprazole on parietal cells and enterochromaffin-like cells in rats: a comparison with omeprazole.	2002	11931530
[Regeneration of the gastric epitheliocytes during treatment of duodenal ulcer with pariet].	2002 Apr	12046531
Proton pump inhibitor modifies inflammatory reaction in human gastric mucosa infected by Helicobacter pylori.	2002 Apr	11966546
Levofloxacin based regimens for the eradication of Helicobacter pylori.	2002 Dec	12468950
Treatment and management of Helicobacter pylori infection.	2002 Dec	12441037
The pharmacology and clinical relevance of proton pump inhibitors.	2002 Dec	12441035
[Cause and prevention of nocturnal gastric acid breakthrough].	2002 Feb	11979888
[Proton pump inhibitors: Rabeprazole].	2002 Feb	11979863
[Continuation of acid suppression therapy after H. pylori eradication].	2002 Feb	11979841
[Minocycline-containing eradication therapy for patients with clarithromycin-resistant Helicobacter pylori infection].	2002 Feb	11979825
[Second line treatment regimen of PPI + AMPC + MNZ for patients with clarithromycin-resistant Helicobacter pylori infection].	2002 Feb	11979824
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].	2002 Feb	11979823
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].	2002 Feb	11979821
[Dual therapy for Helicobacter pylori resistance to anti microbial agents].	2002 Feb	11979819
[Pharma-clinics medication of the month. Rabeprazole (Pariet)].	2002 Jan	11899500
Gateways to clinical trials.	2002 Jan-Feb	11980386
[Evaluation of efficacy, safety and tolerability rabeprazole in treatment of acid-peptic diseases ].	2002 Jan-Mar	12184168
Rabeprazole.	2002 Jan-Mar	12082341
Proton pump inhibitors--differences emerge in hepatic metabolism.	2002 Jul	12236477
Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.	2002 Jul	12181872
Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.	2002 Jul	12144580
Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).	2002 Jul	12141813
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.	2002 Jul	12121503
The efficacy of lafutidine in improving preoperative gastric fluid property: a comparison with ranitidine and rabeprazole.	2002 Jul	12088958
Proton pump inhibitors: an update.	2002 Jul 15	12152963
Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials.	2002 Jul 15	12119060
Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers.	2002 Jul-Aug	12235924
Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.	2002 Jun	12094846
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.	2002 Jun	12030958
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.	2002 May	12058887
Combination drug therapy for gastroesophageal reflux disease.	2002 May	11978171
A modification of the quininium resin test for assessing gastric acidity.	2002 May	11966494
Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease.	2002 Nov	12452397
Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.	2002 Nov	12431607
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study.	2002 Nov	12425542
Restoration of acid secretion following treatment with proton pump inhibitors.	2002 Nov	12404233
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.	2002 Nov	12390102
A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication.	2002 Oct	12412995
Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?	2002 Oct	12385470
Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.	2002 Oct	12269976
Gateways to Clinical Trials.	2002 Sep	12428432
[The short term effect of rabeprazol versus omeprazole on symptom relief of duodenal ulcer].	2002 Sep	12421488
Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions.	2002 Sep	12369444

Patents

Sample Use Guides

In Vivo Use Guide

Erosive or Ulcerative Gastroesophageal Reflux Disease: 20 mg delayed-release tablet to be taken once daily for four to eight weeks. Duodenal Ulcers: 20 mg delayed-release tablet to be taken once daily after the morning meal for a period up to four weeks. Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome: The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg QD and 60 mg BID have been administered

Route of Administration: Oral

In Vitro Use Guide

The MICs of rabeprazole sodium (RPZ) against 133 clinical Helicobacter pylori strains revealed a higher degree of activity. The 133 H. pylori strains tested were recent clinical isolates from different patients with chronic gastritis and gastric and/or duodenal ulcer. The final concentrations prepared in the wells of the microplates were from 0.031 to 64 μg/ml for RPZ.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:39:45 GMT 2023` Edited by `admin` on `Fri Dec 15 16:39:45 GMT 2023`
Record UNII	3L36P16U4R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RABEPRAZOLE SODIUM

Official Name

English

ACIPHEX

Brand Name

English

E-3810 SODIUM

Code

English

SODIUM RABEPRAZOLE

Common Name

English

RABEPRAZOLE SODIUM [ORANGE BOOK]

Common Name

English

RABEPRAZOLE SODIUM [JAN]

Common Name

English

LY307640 SODIUM

Code

English

LY-307640 SODIUM

Code

English

NSC-759270

Code

English

RABEPRAZOLE NA [VANDF]

Common Name

English

RABEPRAZOLE SODIUM [USP MONOGRAPH]

Common Name

English

RABEPRAZOLE SODIUM [USAN]

Common Name

English

IDIAZOLE

Brand Name

English

RABEPRAZOLE SODIUM [EP MONOGRAPH]

Common Name

English

2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]benzimidazole sodium salt

Common Name

English

RABEPRAZOLE NA

Common Name

English

Rabeprazole sodium [WHO-DD]

Common Name

English

RABEPRAZOLE SODIUM SALT

Common Name

English

RABEPRAZOLE SODIUM [MART.]

Common Name

English

PARIET

Brand Name

English

RABEPRAZOLE SODIUM [USP-RS]

Common Name

English

RABEPRAZOLE SODIUM SALT [MI]

Common Name

English

1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT

Common Name

English

Code System Code Type Description

ChEMBL

CHEMBL1219

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

CHEBI

8769

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

SMS_ID

100000090030

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

MERCK INDEX

m9476

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

Merck Index

DAILYMED

3L36P16U4R

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

EVMPD

SUB04192MIG

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

FDA UNII

3L36P16U4R

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

PUBCHEM

14720269

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

RXCUI

226868

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

RxNorm

RS_ITEM_NUM

1598019

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

USAN

GG-101

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

DRUG BANK

DBSALT000552

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

EPA CompTox

DTXSID3044205

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

NSC

759270

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

NCI_THESAURUS

C80692

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

CAS

117976-90-6

Created by admin on Fri Dec 15 16:39:45 GMT 2023 , Edited by admin on Fri Dec 15 16:39:45 GMT 2023

PRIMARY

Related Record Type Details


					32828355LL

RABEPRAZOLE

PARENT -> SALT/SOLVATE


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE


					081I12ZA58

CYTOCHROME P450 2C19

METABOLIC ENZYME -> SUBSTRATE


					5XH0X84AHJ

RABEPRAZOLE SODIUM MONOHYDRATE

SOLVATE->ANHYDROUS


					P4K2NXA5CQ

POTASSIUM-TRANSPORTING ATPASE SUBUNIT BETA

TARGET -> INHIBITOR

Related Record Type Details


					O5O9ZS633T

1-(1H-BENZIMIDAZOL-2-YL)-3-METHYL-4-OXO-1,4-DIHYDROPYRIDINE-2-CARBOXYLIC ACID

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					ZSW7NEY2NI

4-DESMETHOXYPROPOXYL-4-METHOXY S-DEOXO RABEPRAZOLE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					619CVM6HOK

2-BENZIMIDAZOLETHIOL

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					17Q1V00385

RABEPRAZOLE N-OXIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					304S7E320P

RABEPRAZOLE THIOETHER

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					2YP19K112N

2-(((4-CHLORO-3-METHYLPYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE, (±)-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					5YB1T296OD

RABEPRAZOLE SULFONE N-OXIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					I2E100O20P

RABEPRAZOLE SULFONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					5YB1T296OD

RABEPRAZOLE SULFONE N-OXIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					17Q1V00385

RABEPRAZOLE N-OXIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					L6M23VJ488

4-DESMETHOXYPROPOXYL-4-METHOXY RABEPRAZOLE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					CV8118UZEW

2-BENZIMIDAZOLINONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					619CVM6HOK

2-BENZIMIDAZOLETHIOL

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					304S7E320P

RABEPRAZOLE THIOETHER

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					L6M23VJ488

4-DESMETHOXYPROPOXYL-4-METHOXY RABEPRAZOLE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					I2E100O20P

RABEPRAZOLE SULFONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					174J7GUY1B

DISODIUM 1-BENZIMIDAZOL-2-YL-3-METHYL-4-OXO-1,4-DIHYDROPYRIDINE-2-CARBOXYLATE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					CV8118UZEW

2-BENZIMIDAZOLINONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					2YP19K112N

2-(((4-CHLORO-3-METHYLPYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE, (±)-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					ZSW7NEY2NI

4-DESMETHOXYPROPOXYL-4-METHOXY S-DEOXO RABEPRAZOLE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:

Related Record Type Details


					32828355LL

RABEPRAZOLE

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10551440Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20973lbl.pdf

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10551440
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20973lbl.pdf

C_max

T_1/2